Endocrinologic and Metabolic Drugs Advisory Committee #74

Food and Drug Administration
Center for Drug Evaluation and Research

Bethesda Holiday Inn, 8120 Wisconsin Avenue, Bethesda MD

May 19, 2000

a presentation of the data and rationale for the regulatory action regarding the withdrawal from the U. S. market of Rezulin® (troglitazone, Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert) for the treatment of type 2 diabetes mellitus.

Agenda

10:00 Open Public Hearing

11:00 FDA Presentation: Murray M. Lumpkin, M.D.
Deputy Center Director for Review Management

12:00 Lunch

1:00 Parke Davis Pharmaceutical Presentation: Peter B. Corr, Ph.D.
President, Warner Lambert/Parke Davis
Pharmaceutical Research and Development

1:30 Comments

2:00 Adjourn